'For the quarter ending Sept 2023, standalone Net sales (including other operating income) of Pfizer has declined 9.77% to Rs 575.21 crore compared to quarter ended Sept 2022.  Operating profit margin has declined from 36.35% to 31.75%, leading to 21.18% decline in operating profit to Rs 182.61 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.44% to 15.71%.   Purchase of finished goods cost rose from 11.67% to 14.84%.   Employee cost increased from 14.36% to 16.84%.   Other expenses rose from 17.19% to 18.38%.   

Other income up 48.80% to Rs 36.07 crore.  PBIDT fell 14.55% to Rs 218.68 crore.  Provision for interest fell 19.23% to Rs 2.73 crore.  Loan funds rose to Rs 42.63 crore as of 30 September 2023 from Rs 39.73 crore as of 30 September 2022.  Inventories declined from Rs 456.56 crore as of 30 September 2022 to Rs 399.08 cro...

• 

  (17-Jan-2026)

  Federal Bank

  Healthy all-round performance
• 

  (17-Jan-2026)

  Fedbank Financial Services

  AUM growth accelerates to 17%, spreads improve
• 

  (17-Jan-2026)

  Tech Mahindra

  NP up 14.1% YoY to Rs 1122 crore in Q3FY2026
• 

  (17-Jan-2026)

  Wipro

  Revenue up 5.5% yoy to Rs 23555.8 crore in Q3FY2026